Covid vaccine maker Novavax sees a pathway to survival but it wont be easy

Cash-strapped Covid vaccine Novavax still faces a nunber of challenges, chiefly competing with Pfizer and Moderna in the U.S. commercial market this fall.

from Health and Science https://ift.tt/fRlLSMz
https://ift.tt/qQvPOyp
https://ift.tt/lBTn2eL